CRIS

+ Watchlist + Portfolio

Curis, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.83
52-Week Range: $0.80 – $34.40
Market Cap: $1.95M
P/E (TTM): 0.61
EPS (TTM): 1.32
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.33
PEG Ratio: —
Return on Equity: —
Return on Assets: -93.23%
Gross Margin: 0.00%
Operating Margin: -833.40%
Profit Margin: 0.00%
Current Ratio: 0.49
Debt/Equity: 0.22
Total Debt: $1.04M
Free Cash Flow: $-15.77M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-2.35M

CRIS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$10.16M	$10.02M	$10.91M	$9.44M
Cost of Revenue	$257.00K	$212.00K	$98.00K	$45.00K
Gross Profit	$9.90M	$9.81M	$10.81M	$9.40M
Research & Development	$43.28M	$39.50M	$38.56M	$28.25M
Selling, General & Admin	$19.65M	$18.65M	$16.79M	$14.05M
Operating Expenses	$62.92M	$58.14M	$55.35M	$42.30M
Operating Income	-$53.02M	-$48.33M	-$44.54M	-$32.90M
EBITDA	-$51.67M	-$45.14M	-$42.57M	-$5.23M
Pretax Income	-$56.67M	-$47.41M	-$43.39M	-$7.58M
Net Income	-$56.67M	-$47.41M	-$43.39M	-$7.58M
Diluted EPS	-244.00	-179.20	-137.60	-11.60
Diluted Shares	233481	264664	315314	658201

CRIS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.66M	$26.68M	$20.00M	$5.06M
Receivables	$2.98M	$2.79M	$3.35M	$0.00
Current Assets	$92.12M	$60.91M	$26.39M	$6.92M
Total Assets	$108.85M	$77.28M	$41.27M	$19.97M
Current Liabilities	$10.01M	$22.02M	$19.03M	$14.08M
Total Debt	$3.94M	$2.79M	$2.95M	$1.62M
Total Liabilities	$62.30M	$57.61M	$47.26M	$14.50M
Retained Earnings	-$1.15B	-$1.20B	-$1.24B	-$1.25B
Shareholders' Equity	$46.55M	$19.67M	-$6.00M	$5.46M
Working Capital	$82.11M	$38.89M	$7.36M	-$7.16M

CRIS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$54.34M	-$38.43M	-$39.56M	-$27.20M
Capital Expenditure	-$416.00K	—	—	—
Free Cash Flow	-$54.75M	-$38.43M	-$39.56M	-$27.20M
Depreciation & Amortisation	$233.00K	$255.00K	$203.00K	$169.00K
Stock-Based Compensation	$6.75M	$6.00M	$5.93M	$4.02M
Investing Cash Flow	$33.02M	$37.79M	$29.44M	$2.50M
Financing Cash Flow	$867.00K	$7.58M	$3.44M	$9.77M
Net Change in Cash	-$20.45M	$6.93M	-$6.68M	-$14.94M

CRIS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.38M	$2.75M	$3.18M	$1.14M	$0.00	$0.00
Cost of Revenue	$14.00K	$16.00K	$15.00K	$0.00	$0.00	$0.00
Gross Profit	$2.37M	$2.73M	$3.16M	$1.14M	$0.00	$0.00
Research & Development	$8.54M	$7.46M	$6.43M	$5.83M	$6.45M	$6.71M
Selling, General & Admin	$3.98M	$3.53M	$3.65M	$2.88M	$5.07M	$3.23M
Operating Expenses	$12.52M	$10.98M	$10.09M	$8.71M	$11.52M	$9.94M
Operating Income	-$10.16M	-$8.25M	-$6.92M	-$7.57M	-$11.52M	-$9.94M
EBITDA	-$10.10M	-$8.21M	-$6.89M	$19.97M	-$11.51M	-$9.93M
Pretax Income	-$10.62M	-$8.59M	-$7.73M	$19.36M	-$24.20M	-$8.58M
Net Income	-$10.62M	-$8.59M	-$7.73M	$19.36M	-$24.20M	-$8.58M
Diluted EPS	-25.00	-13.61	-9.80	24.60	-25.00	-4.02
Diluted Shares	424694	631475	784008	787353	968173	2.14M

CRIS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$20.28M	$10.14M	$9.05M	$5.06M	$15.00M	$5.07M
Receivables	$2.31M	$2.75M	$3.24M	$0.00	—	—
Current Assets	$24.81M	$14.42M	$13.91M	$6.92M	$16.61M	$6.72M
Total Assets	$39.33M	$29.23M	$27.64M	$19.97M	$29.69M	$18.97M
Current Liabilities	$20.12M	$19.37M	$19.91M	$14.08M	$14.97M	$13.68M
Total Debt	$2.64M	$2.31M	$1.97M	$1.62M	$1.34M	$1.04M
Total Liabilities	$45.93M	$43.22M	$42.33M	$14.50M	$16.98M	$14.28M
Retained Earnings	-$1.25B	-$1.26B	-$1.27B	-$1.25B	-$1.27B	-$1.28B
Shareholders' Equity	-$6.61M	-$13.99M	-$14.69M	$5.46M	$12.71M	$4.70M
Working Capital	$4.69M	-$4.95M	-$6.00M	-$7.16M	$1.64M	-$6.95M

CRIS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$7.25M	-$8.01M	-$5.57M	-$6.37M	-$9.00M	-$9.65M
Free Cash Flow	-$7.25M	-$8.01M	-$5.57M	-$6.37M	-$9.00M	-$9.65M
Depreciation & Amortisation	$59.00K	$42.00K	$32.00K	$36.00K	$8.00K	$8.00K
Stock-Based Compensation	$1.16M	$1.14M	$924.00K	$795.00K	$575.00K	$569.00K
Investing Cash Flow	$0.00	$0.00	$0.00	$2.50M	$0.00	$0.00
Financing Cash Flow	$7.54M	-$2.13M	$4.48M	-$119.00K	$18.94M	-$282.00K
Net Change in Cash	$285.00K	-$10.14M	-$1.09M	-$3.99M	$9.94M	-$9.93M

Market Snapshot

About

Curis, Inc. is a biotechnology company focused on developing innovative therapeutics for the treatment of cancer. Headquartered in Lexington, Massachusetts, the company's pipeline includes targeted small molecule and immuno-oncology drug candidates. Curis's lead programs include emavusertib, a selective oral IRAK4 inhibitor for hematologic and solid tumors, and CA-4948, an IRAK4 inhibitor being evaluated in collaboration with Aurigene Discovery Technologies. The company has strategic partnerships with major pharmaceutical companies and focuses on precision medicine approaches to cancer treatment.